Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Institut Pasteur De Lille

Veronique Pancre

Claude Auriault

Andre Capron

François Lemonnier

Yu-Chun Lone

Anthony Pajot

Michel Joseph

The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2HLA-DR1&#x3b2;2m&#xb0;IA&#x3b2;&#xb0;. The invention also relates to methods of using a transgenic mouse of the invention.

Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

Novel lymphokine for suppressing platelet activation

Growing community of inventors

Orchies, France

Veronique Pancre